Eversept Partners’s bluebird bio BLUE Stock Holding History

Eversept Partners’s Portfolio BLUE Stock Details BLUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-5,666	Closed	-$6.44M	–	63
2019 Q4	$6.44M	Buy	+5,666	New	+$6.16M	1.14%	24

Other funds holding BLUE

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Eversept Partners's BLUE Position: Q1 2020 in Review

Eversept Partners sold out of bluebird bio (BLUE) in Q1 2020, closing a stake of 5,666 shares — an estimated $6.44M sold.

Eversept Partners first reported a position in BLUE in Q4 2019 and held it in 1 quarter. The position peaked at $6.44M in Q4 2019. 247 funds tracked by Wall St. Rank hold BLUE as of Q1 2020.

Eversept Partners reported no remaining bluebird bio position as of Q1 2020 after selling out during the quarter.
Eversept Partners sold 5,666 bluebird bio shares in Q1 2020, an estimated $6.44M.
Eversept Partners first reported a position in bluebird bio in Q4 2019 and held it in 1 quarter.
Eversept Partners's bluebird bio position peaked at $6.44M in Q4 2019.
247 funds tracked by Wall St. Rank held bluebird bio as of Q1 2020.

Based on Eversept Partners's 13F filing for Q1 2020, filed 13 May 2020.